Table 2

Impact of allergy status on risk of Plasmodium falciparum clinical episodes

 Age groups (3.5 years)aOR95% CIp Value
LowerUpper
AtopyBoth1.651.202.262.0×10−3
<3.51.380.922.080.124
≥3.52.021.392.932.1×10−4
AsthmaBoth2.121.463.088.0×10−5
<3.51.500.902.500.122
≥3.52.331.503.611.5×10−4
Atopic dermatitisBoth1.050.651.700.842
<3.50.840.491.460.539
≥3.53.151.566.331.3×10−3
RhinoconjunctivitisBoth0.960.651.410.818
<3.51.050.641.720.853
≥3.50.950.601.520.834
Age ≥3.50.480.400.572.7×10−15
Trimestrial incidence1.011.001.011.8×10−6
HbAS0.240.120.473.7×10−5
  • Shown are the p values and adjusted ORs with 95% CIs calculated from the mixed-model analyses. Values for the covariables age (≥3.5 years of age compared with <3.5 years of age), trimestrial incidence of P falciparum clinical episodes and HbAS (β-globin sickle-cell trait; AS compared with AA) are those from the Asthma model analysis. For clarity significant covariables are shown in bold.